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Protected carotid stenting: Safety and efficacy of
the MedNova NeuroShield filter
Sumaira Macdonald, MRCP, FRCR,a Graham S. Venables, DM, FRCP,b Trevor J. Cleveland, FRCS,
FRCR,a and Peter A. Gaines, MRCP, FRCR,a Sheffield, United Kingdom
Objective: Neuroprotection during carotid stenting has the potential to reduce procedural atheroembolic sequelae. We
report the United Kingdom experience of NeuroShield (MedNova Ltd, Horsham, West Sussex, United Kingdom).
Methods: We performed a prospective cohort analysis of 50 consecutive patients (50 lesions) in a regional vascular tertiary
referral center (catchment area one million) that provides an institutional service for the short term. The subjects were all
the patients referred for carotid stenting after preassessment by a multidisciplinary team. All the patients underwent
pretreatment with antiplatelet agents. Forty-two patients had atherosclerotic stenosis of the carotid bifurcation between
70% and 95% (with North American Symptomatic Carotid Endarterectomy Trial criteria). Six patients had restenosis
after endarterectomy. Two had previous local radiotherapy. Forty-two patients were symptomatic (amaurosis fugax/
central retinal artery occlusion in 11 cases, and hemispheric transient ischemic attack/cerebrovascular accident in 31
cases). Eight patients were asymptomatic with bilateral high-grade stenoses, with six cases before coronary artery bypass
grafting. The intervention performed was protected primary carotid stenting. Outcome measures were procedural
atheroembolic events, including all-stroke and death rates up to 30 days, and analysis of retrieved debris in a subset of 11
cases.
Results: The technical success rate was 50/50 (100%) for stenting and 49/50 (98%) for filter placement/retrieval.
Technical complications comprised nonsymptomatic spasm at the filter site (flow limiting in two cases and non–flow
limiting in five cases). Procedural events were one minor stroke (patient fully recovered within 48 hours) in a complex
clinical setting and one ventricular fibrillation arrest in a patient before coronary artery bypass grafting who was
resuscitated without neurologic event. At 30 days, the death or major disability from stroke rate was 2/50 (4%). No cases
were atheroembolic. The all-stroke/death rate was 3/50 (6%). The two deaths were the result of a fatal hemorrhagic
stroke that occurred at 4 days and was thought to be caused by reperfusion and a perforated ventricle caused by a
temporary pacing wire. One femoral pseudoaneurysm followed failed closure device deployment and required percuta-
neous thrombin injection. The mean particle number per patient was 12 (range, 0 to 41). The mean particle diameter was
284.9 m (range, 31 to 1430 m). The mean ellipsoid volume load was 0.1602 mm3 (range, 0.0005 to 0.1968 mm3).
Conclusion: Carotid stenting protected with NeuroShield is safe. The filter traps embolic debris liberated during the
procedure. (J Vasc Surg 2002;35:966-72.)
Angioplasty/stenting for carotid artery stenosis has
been investigated for two decades but has not yet gained
widespread acceptance because of the excellent published
results of conventional surgery and the low perioperative
risk of embolic stroke. The current periprocedural neuro-
logic event rate for unprotected carotid artery angioplasty/
stenting ranges between 5.3% and 8.2%,1-5 as compared
with a 5.8% perioperative total neurologic event rate in the
North American Symptomatic Carotid Endarterectomy
Trial (NASCET).6 A joint literature review and multicenter
survey of unprotected carotid stenting with 24 responders
indicated an all-stroke and mortality rate of 5.8%.7
The results of the carotid and vertebral artery translu-
minal angioplasty study (CAVATAS), a multicenter random-
ized trial, reported no difference in the primary outcome
measures within 30 days of treatment with either carotid
endarterectomy (CEA) or angioplasty. The event rate of
this randomized trial was 6% in both limbs for disabling
stroke/death and approximately 10% in both limbs for any
stroke lasting longer than 7 days or death. It was concluded
that CEA and angioplasty are equivalent in safety and
efficacy but that angioplasty had advantages with respect to
nerve injury and cardiac complications.8
Although the current global status suggests that percu-
taneous carotid intervention may be an alternative to CEA,
at least for certain indications, procedural cerebral emboli-
zation still occurs. This may happen despite advances in
guidewire/stent technology. This risk is highlighted by a
recent stopped trial.9
Faced with documented embolic complications during
carotid stenting with potential risk of intracerebral arterial
occlusion with an unpredictable clinical expression, it
would seem logical to implement the use of and to assess
the outcomes of neuroprotection. The MedNova Neuro-
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Shield (MedNova Ltd, Horsham, West Sussex, United
Kingdom) has a Conformity European (CE) mark and US
Food and Drug Administration approval for its coronary
counterpart, the CardioShield; Food and Drug Administra-
tion approval for NeuroShield is pending. This filter pro-
tection system is described in detail elsewhere.10 We aimed
to show the safety and efficacy of the NeuroShield device
and analyze the retrieved material in a consecutive subset.
PATIENTS AND METHODS
Patient demographics. Fifty patients (50 lesions) un-
derwent carotid stenting with cerebral protection between
December 1999 and May 2001. The median age was 64.5
years (range, 47 to 80 years), and there were 14 women and
36 men. Forty-three patients underwent treatment at our
center, and seven at other centers in the United Kingdom.
Cases at our vascular institute were supported by the pres-
ence of one of the two experienced vascular radiologists
from our center acting as proctor.
Full approval was granted from the Local Ethics Com-
mittee at our center for the first 11 patients recruited as part
of the CE marking study. The remaining 39 patients un-
derwent protected carotid stenting reflecting a progression
of technique, with an approved device.
Symptoms. Forty-two patients were symptomatic,
and all underwent treatment within 6 months of the onset
of symptoms. Twenty-six of these patients had ipsilateral
hemispheric transient ischemic attack, and five had ipsilat-
eral hemispheric cerebrovascular accident. Three of these
cases were recovered strokes with no residual deficit, and
two had mild residual dysphasia. Eleven patients had ipsi-
lateral amaurosis fugax or central retinal artery occlusion.
Eight patients were asymptomatic but had bilateral high-
grade internal carotid artery (ICA) stenoses or occlusion,
which when summated exceeded 160%. Six of these pa-
tients were awaiting coronary artery bypass grafting.
Lesion characteristics. Forty-two patients underwent
treatment for atherosclerotic stenosis of the ICA (between
70% and 95%), one for radiotherapy-related stenosis of the
ICA and one for radiotherapy-related stenosis of the com-
mon carotid artery. Six patients underwent treatment for
symptomatic restenosis at a previous endarterectomy site.
The median lesion stenosis was 90% (range, 70% to 95%).
In two cases, the contralateral ICA was between 70% and
99% stenosed, and in 10 cases, it was occluded.
Assessment and recruitment. All the patients under-
went preassessment by a multidisciplinary team comprised
of vascular radiologists, vascular surgeons, and a neurolo-
gist with an interest in stroke prevention. All the patients
underwent screening duplex scan assessment of the ex-
tracranial carotid arteries. In most cases, prior computer-
ized tomography or magnetic resonance imaging of the
brain had been performed. In those patients with 50% or
greater lumen diameter loss of the bifurcation/ICA on
duplex scan results, arch aortography was performed.
Stenting then was usually performed as a second-stage
procedure after angiographic confirmation of duplex scan
findings and exclusion of arch vessel disease.
This approach has cost implications, but the current
literature supports the premise that the accuracy of carotid
Doppler scan does not justify its use as the sole basis of
selecting appropriate patients for carotid intervention.11,12
Because magnetic resonance angiography is currently un-
validated against the gold standard catheter angiography,
arch aortography is routinely performed before carotid
intervention.
Eligibility criteria. All patients who were symptom-
atic with an ICA stenosis of 70% lumen diameter loss
(with NASCET criteria) ipsilateral to hemispheric/ocular
symptoms and all patients who were asymptomatic with
bilateral combined ICA stenosis 160% before coronary
artery bypass grafting or otherwise were considered for
stenting. Patients with tortuous vascular anatomy, preclud-
ing safe endovascular access to the lesion, underwent treat-
ment with CEA. Patients with arch origin disease were not
treated from the femoral approach and were not included in
this cohort.
Exclusion criteria. The exclusion criteria included ex-
clusion criteria for carotid stenting (Appendix A, online
only) and additional specific criteria for neuroprotection
with NeuroShield.
Exclusion criteria for neuroprotection. Patients
were excluded from the study for disease, marked tortuos-
ity, or caliber less than 4 mm or more than 6 mm at the
proposed filter deployment site in the distal ICA. Patients
were also excluded if they were not undergoing full anti-
platelet therapy (aspirin or dypiridamole and clopidogrel
bisulfate).
Protected carotid stenting protocol. All the patients
were undergoing therapy with either aspirin or dipyridam-
ole plus either 300 mg clopidogrel bisulfate (Plavix, Sanofi-
Synthelabo, Guildford, Surrey, United Kingdom) 1 hour
before stenting or 75 mg clopidogrel bisulfate daily for 3
days before stenting. Primary carotid stenting was per-
formed according to our protocol.13 All the patients were
given 5000 units of heparin at femoral access. Activated
clotting times were not routinely measured. The literature
indicates that a 5000 unit dose of heparin will maintain the
ACT within therapeutic range (at least twice that of healthy
range) for 45 minutes or more in most cases.14 In proce-
dures lasting longer than 45 minutes, a further dose of
heparin (1000 to 2000 units) was administered. In addi-
tion, the routine use of closure devices for the groin wound
makes ACT measurements irrelevant.
With roadmapping, the 0.014-inch diameter wire inte-
gral to the NeuroShield filter was used to negotiate the
lesion (Appendix B, online only). The filter presented a
crossing profile only slightly larger (4.5F) than an unin-
flated coronary-type balloon routinely used for (prestent)
predilatation. The generation 2 NeuroShield was used
throughout the cohort (Fig 1).
The filter was deployed in the distal ICA, on average 4
cm upstream of the target lesion. The 0.014-inch wire
integral to the filter element then became the procedural
guidewire over which subsequent stages were performed.
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If the lesion could not be negotiated with NeuroShield,
because of tortuosity or the degree of stenosis, “buddy-
wiring” was performed. This comprised passage of an
0.014-inch wire (St Ex Hannibal stent support guidewire,
Boston Scientific Corporation, Natick, Mass) to first cross
the lesion, straighten out the vessel, and allow passage of
the NeuroShield filter (Fig 2). Predilatation before place-
ment of the NeuroShield was necessary if an extremely tight
lesion could not be negotiated with the filter. The rationale
was that although the brain would be unprotected from
debris generated by predilatation, the remaining stenting
stages would be protected.
The NeuroShield filter was retrieved with a dedicated
catheter after completion angiography to evaluate final
appearances and to establish whether the filter had become
occluded with a large embolic volume load. Hemostasis at
the access site was routinely secured with a closure device
(AngioSeal, St Jude Medical, Minnetonka, Minn). Patients
were assessed neurologically for 24 hours and discharged if
their clinical condition was satisfactory. All patients were
discharged with 75 mg clopidogrel bisulfate daily for a
fortnight after stenting and were reviewed at 30 days in the
outpatient clinic for neurologic examination by the senior
neurologist.
Analysis of embolic debris. Filters were photo-
graphed to provide a gross record. The filter then was
dismantled, and further photographic records were made.
Macroscopic particles were extracted with and measured
against a standard scale. The remaining retrieved material
was passed through a 5-m cellulose nitrate filter and
sequentially processed through ascending grades of alcohol
(70% to 99%) xylene and then mounted in hot paraffin wax.
Four-millimeter sections were cut and stained with hema-
toxylin and eosin dyes. Particle dimensions then were mea-
sured microscopically with a graticule. Sub–30m particles
were excluded from analysis. Mean particle diameters, fre-
quency, and volume load of the retrieved debris thus were
recorded.
Data collection. Data were collected prospectively.
Lesion morphology was recorded after review of procedural
angiographic images, preprocedure duplex scan, and arch
aortography. Demographic and clinical variables recorded
included age, sex, patient symptoms, and interval between
last neurologic event and intervention, reason for treatment
in asymptomatic individuals, drug treatment, and vascular
risk factors. Morphologic variables considered were site,
severity, and cause of stenosis and status of the contralateral
ICA. Procedural variables recorded included filter size,
technical complications and management, and any predila-
tation details.
The primary clinical endpoints were procedural athero-
embolic events, including the all-stroke and mortality rates
within 30 days. The all-stroke rate comprised minor, major
disabling, and major nondisabling stroke. Secondary end-
points included technical complications and retrieved em-
bolic load in a subset.
Definitions. Transient ischemic attack was defined as a
new neurologic deficit persisting for less than 24 hours with
complete resolution or return to baseline. Minor stroke was
defined as a new neurologic deficit that persisted for more
than 24 hours but completely resolved or returned to
baseline within 1 week. Major stroke nondisabling was de-
fined as a new neurologic deficit that persisted after 7 days.
The stroke was categorized as nondisabling if the patient
scored 0 to 2 on the Oxford Modified Handicap Score.15
Major stroke disabling was defined as a new neurologic
deficit that persisted after 7 days. The stroke was catego-
rized as disabling if the patient scored a 3 or more on the
Oxford Modified Handicap Score.
RESULTS
All the results were analyzed on an intention-to-treat
basis.
Technical success. All 50 carotid stenoses were suc-
cessfully stented, 49 (98%) with NeuroShield protection.
One patient’s lesion could not have the protection placed
because of marked tortuosity. The patient underwent un-
complicated unprotected stenting.
Technical complications. In five cases, because of
tight lesions, a Hannibal 0.014-inch wire was passed after
unsuccessful NeuroShield placement and was used to
“buddy” the protection system. Three of these cases re-
quired predilatation with a 3-mm balloon. No clinical
embolic events accompanied these maneuvers. In two
other cases, there was flow-limiting spasm associated with
the filter, which was treated with glycerol trinitrate (GTN)
and in one case, filter advancement. Again, neither case was
associated with neurologic events. In five patients, there
was non–flow limiting spasm (Fig 3) treated with GTN.
There were no dissections.
Procedural outcomes. There were no postangio-
graphic strokes. All the patients initially evaluated with arch
Fig 1. Diagram representation of NeuroShield filter (MedNova Ltd, Horsham, West Sussex, United Kingdom).
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angiography were referred for protected carotid stenting,
surgery, or best medical therapy.
There were no procedural transient ischemic attacks
and one minor stroke. This patient was dysphasic after left
carotid stenting and fully recovered after 48 hours. The
patient had von Willebrand’s disease and as a result had
aspirin omitted from our usual regime. There were no
periprocedural major strokes.
Two cardiac complications occurred. In one patient
awaiting coronary surgery, ventricular fibrillation was suc-
cessfully reversed. The other patient had prolonged brady/
tachyarrhythmia after a previous arch aortogram, and a
temporary transvenous pacing wire was placed before stent-
ing. After successful stent placement, the pacing wire was
removed in the coronary care unit, after which the patient
had an asystolic arrest from which resuscitation was not
possible. Autopsy results showed a perforated right ventri-
cle (thought secondary to placement of the pacing wire)
and hemopericardium as the cause of death.
Thirty-day outcomes. The 30-day death or major
disability from stroke rate was therefore 4% (two of 50), and
there were no major strokes or deaths related to atheroem-
bolic events. There was one neurologic death: a hemor-
rhagic stroke occurring at 4 days after uncomplicated stent-
ing, thought to result from reperfusion injury. This
patient’s contralateral ICA was 50% stenosed, and there
had been no evidence of hemodynamic instability or hyper-
tension after stenting.
The all-stroke/death rate was 3/50 (6%), encompass-
ing the minor stroke with full recovery within 48 hours. In
patients who were symptomatic, the all-stroke/death rate
was 3/42 (7%) and the death/major disability rate 2/42
(4.7%). One femoral pseudoaneurysm followed unsuccess-
ful placement of an AngioSeal device (St Jude Medical) and
was treated with percutaneous thrombin injection.
Retrieved debris. The filter contents were analyzed
formally in the first 11 patients and contained macroscopic
debris in eight cases (75%). The number of particles ranged
from 0 to 41 (mean, 12), with particle sizes of 31 to 1430
m (mean, 284.9 m). The debris included fibrin, choles-
terol clefts, organized thrombus, and red and white cell
aggregates (Fig 4).
DISCUSSION
During CEA, neurologic events are known to correlate
with the frequency of transcranial Doppler scan events, and
these are manifested as overt clinical events or may be
covert,16,17 recognized with subsequent cognitive function
testing. Studies made during cardiopulmonary bypass
procedures suggest that the clinical impact of cerebral
microembolization may be underestimated.18 Cognitive
function testing on a small CAVATAS subset showed a
similar decline in performance in each limb of the trial.19
However, the angioplasty group were heterogeneous (in-
cluding primary and secondary stenting) and neuroprotec-
tion was not used. To our knowledge, there is no targeted
work on cognitive deficit after protected carotid stenting,
but this work is ongoing at our center.
The most common cause of stroke during carotid an-
gioplasty/stenting is thought to be embolic in origin.20
Therefore, some form of device designed to reduce or
eliminate the embolic load to the brain is considered ad-
vantageous. Three philosophies are presently being inves-
tigated: balloon occlusion of the ICA and subsequent
aspiration of any particles (eg, PercuSurge), filter placement
(eg, NeuroShield and Angioguard), or flow reversal in the
ipsilateral ICA (eg, ArteriA). No available device is cur-
rently perfect, and modifications are ongoing. Balloon oc-
Fig 2. Demonstration of “buddy-wire” technique to facilitate
negotiation of tight/tortuous lesion with NeuroShield filter (Med-
Nova Ltd, Horsham, West Sussex, United Kingdom).
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clusion carries the risk of intolerance of the device because
of brain hypoperfusion during device deployment, particu-
larly in patients with significant contralateral carotid dis-
ease.21 For this reason, filtration with continued flow
through the filter has potential advantages. A number of
such devices have CE marks, one of which is the Neuro-
Shield. Positive features of this filter include its being free
on the wire (within certain constraints), allowing a few
millimeters of wire movement without filter movement and
complete withdrawal of the filter element into an expansile
catheter at completion, facilitating hazard-free removal of
the contained particles. At present, the method of flow
reversal in the ICA is experimental with no CE marked
device.
The generation of NeuroShield used in this cohort has
the filter delivery integral with the 0.014-inch wire used to
traverse the lesion. The whole system is therefore less
sensitive to torque control, making negotiation of the
stenosis difficult at times. To help this, it was occasionally
necessary to cross the lesion first with an 0.014-inch bare
wire and then follow this with the protection system (“bud-
dy wire”). The latest NeuroShield development allows the
lesion to be first crossed with a bare wire and the filter
subsequently loaded and deployed over this wire (Appen-
dix C, online only).
All of the current protection devices present a larger
profile on the wire where either the balloon or filter are
situated. When tight lesions are treated, these may not
allow free passage of this larger diameter section. There-
fore, predilatation may be necessary, with subsequent care-
ful passage of the protection device. The current literature
supports the theory that atheroemboli are released during
all stages of carotid angioplasty/stenting but predomi-
nantly at stent placement and postdilatation,9,22-24 and
these stages are still protected if predilatation is necessary
for filter placement.
Ex vivo analysis results10 indicated that although small
numbers of atheroemboli were released during filter pas-
Fig 3. Illustration of non–flow-limiting spasm.
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sage and some were not captured, most particles, specifi-
cally those of large size, were released during angioplasty/
stenting and the filter captured 88% of these. To our
knowledge, there is no in vivo work quantifying untrapped
particles, but our series, as do others,23 show that particles
are trapped in filter systems.
Whichever system is deployed in the ICA, there is a
potential for spasm in this vessel, and this was seen in this
cohort. However, in only two cases was this flow limiting
and this was successfully treated in two ways: the adminis-
tration of 200 g aliquots of GTN, with or without the
gentle advancement of the filter, with guide-wire advance-
ment. Both methods were successful. However, complete
resolution of the spasm seemed to require the removal of
the irritation (ie, the filter). Despite any spasm, good ICA
flow was seen once the spasm had been treated. This
allowed the stenting procedure to be completed as planned
and then the filter retrieved.
The outcome that is most relevant to this device is the
periprocedural neurologic event rate, because cerebral pro-
tection should confer no advantage outside this period.
The periprocedural stroke rate in this series was 2% (ie, the
procedural minor stroke that fully resolved in 48 hours in a
patient with von Willebrand’s disease). The stroke-related
mortality in this group was hemorrhagic and thought to be
caused by reperfusion injury 4 days after stenting. This is a
complication common to CEA and stenting and not likely
to be affected by the use or otherwise of cerebral protection
systems.
At 30 days, emphasis should be placed on death or
major disability from stroke, because this outcome measure
was considered to best reflect the overall net benefit of
therapy in a recent Cochrane systematic review on CEA for
symptomatic carotid stenosis.25 The European Carotid
Surgery Trial reported all disabling/fatal stroke/death and
CAVATAS reported disabling stroke/death and any stroke
more than 7 days/death. NASCET reported an all-stroke/
death rate, but their definition of a minor event was not
given and their definition of major stroke was “causing a
functional deficit 90 days.” By these criteria, the most
important outcome measure in our series, the major
stroke/death rate at 30 days, remains 2/50 (4%).
The Cochrane review considered that hemorrhagic
stroke, cardioembolic stroke, and non–stroke related death
added variability (noise) to the outcome. It is unfortunate
that our death/major disability from stroke rate reflects a
hemorrhagic stroke and a non–stroke related death. If we
consider these to reflect noise, we have no significant events
at 30 days.
Even if the total event rate (including minor stroke) is
analyzed in the symptomatic subset (3/42; 7%), this is
clearly lower than in two recent reports of carotid endarter-
ectomy from Germany and the United States. In these
series, patients were evaluated by an unbiased observer (a
neurologist), and the stroke and death rates were 11.1%
and 11.4%.26,27
CONCLUSION
The MedNova NeuroShield is safe and traps embolic
debris generated by percutaneous carotid intervention. A
randomized trial is necessary to accurately correlate the use
of neuroprotection with a reduced neurologic event rate.
We thank our colleagues at centers at which proctored
protected carotid stenting was performed: Drs Derek
Gould and Richard McWilliams (Royal Liverpool Hospital,
Fig 4. Magnified photograph of collected embolic debris in retrieved filter.
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